Tirzepatide Early Weight Responders Achieve Greater Long-Term Cardiometabolic Benefits with Similar Tolerability

Global obesity affects over 800 million people, leading to severe complications like cardiovascular disease and type 2 diabetes (T2D). Optimizing treatment outcomes often hinges on identifying early indicators of success. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated robust weight reduction and improvements in cardiometabolic risk parameters (CRPs) in the SURMOUNT trials. This post-hoc analysis aimed to determine if early weight response to tirzepatide could predict overall efficacy and tolerability, providing insights into personalized treatment strategies and patient management.

This was a post-hoc exploratory analysis of data from the phase 3, multicenter, randomized, placebo-controlled, double-blind SURMOUNT-1 (SM-1) and SURMOUNT-2 (SM-2) trials. The analysis included tirzepatide-treated participants with obesity or overweight from SM-1 (n=1775) and SM-2 (n=609), totaling N=2384. Participants were categorized as early responders (ERs; ≥5% weight reduction) or non-early responders (non-ERs; <5% weight reduction) at Week 8. Outcomes, including weight reduction, cardiometabolic risk parameters (CRPs), tolerability, and hypoglycemia, were assessed at Week 72 using logistic regression and mixed models for repeated measures.

Written by TitrateLab, separately from the study summarized above.